Background Image
Menu

Latest News

Apex Molecular Ltd appoints Dr Jason Tierney as a Medicinal Chemistry Consultant

7 November 2024

Apex Molecular Ltd appoints Dr Jason Tierney as a Medicinal Chemistry Consultant

Apex Molecular Limited announces the appointment of Dr Jason Tierney as a medicinal chemistry consultant to work on their external customer medicinal chemistry drug discovery projects. Jason is an experienced Drug Hunter, having over 25 years’ experience in Drug Discovery, both...

Monument Therapeutics secures £1m investment to fund its schizophrenia programme and drive next stage of growth

15 October 2024

Monument Therapeutics secures £1m investment to fund its schizophrenia programme and drive next stage of growth

Manchester, UK, 15 October 2024 - Monument Therapeutics, a precision neuroscience company, today announced a further £1M equity investment by the Forster Foundation, a charitable incorporated organisation. The new investment builds on equity and non-dilutive funding announced in...

LYVA Labs invests £50,000 into health innovators Tectores

25 September 2024

LYVA Labs invests £50,000 into health innovators Tectores

YVA Labs has completed a £50,000 investment into Tectores Ltd, a Wirral-based healthcare company. Tectores’ patented anti-friction technology, PelliTec®, is currently available in a pad, which is worn inside footwear to prevent blisters. The pad has been shown to reduce the...

Monument Therapeutics announces grant of UK patent for neuroinflammation compound MT1980

18 September 2024

Monument Therapeutics announces grant of UK patent for neuroinflammation compound MT1980

MANCHESTER, England, Sept. 17, 2024 - Monument Therapeutics, a stratified medicine company developing novel treatments for areas of high unmet need in psychiatry and neurology, today announced that the United Kingdom Intellectual Property Office ("IPO") has granted UK patent...

First NCFB patient dosed in RESP-X Phase IIa study

17 September 2024

First NCFB patient dosed in RESP-X Phase IIa study

Alderley Park, Cheshire, U.K. Infex Therapeutics, a leading anti-infectives specialist, announces that the first patient has been dosed in a Phase IIa clinical trial for RESP-X, a new anti-virulence therapy to treat Pseudomonas aeruginosa (Pa) infections in non-cystic fibrosis...

QV Bioelectronics delivers breakthrough pre-clinical safety and efficacy results for Electric Field Therapy in the treatment of Glioblastoma

10 September 2024

QV Bioelectronics delivers breakthrough pre-clinical safety and efficacy results for Electric Field Therapy in the treatment of Glioblastoma

• Safety of QV’s novel stimulation regimes demonstrated in large animal studies for up to three months of implantation. • Pre-clinical data demonstrates QV’s breakthrough proprietary stimulation methodology outperforms that of the industry leader in its effectiveness against...

Respected pharma data science pioneer Dr Ben Sidders to spearhead Biorelate's next growth phase as Chief Scientific Officer

6 September 2024

Respected pharma data science pioneer Dr Ben Sidders to spearhead Biorelate's next growth phase as Chief Scientific Officer

Dr Sidders brings two decades of deep data science experience, honed across multiple therapeutic areas at Pfizer and AstraZeneca. He will build on Biorelate's strong track record of leveraging advanced data science methods to extract critical knowledge from vast amounts of...

QV Bioelectronics secures £343,000 from Innovate UK’s Cancer Therapeutics programme to develop a new treatment for childhood brain tumours

5 September 2024

QV Bioelectronics secures £343,000 from Innovate UK’s Cancer Therapeutics programme to develop a new treatment for childhood brain tumours

• The project will adapt QV Bioelectronics’ existing electric field therapy (EFT) technology to develop the world’s first fully implantable EFT device to treat Diffuse Midline Glioma (DMG). • DMG is a highly aggressive childhood brain cancer and ultra-orphan disease with a...

Infex Therapeutics to present RESP-X Phase I data at ERS Congress

3 September 2024

Infex Therapeutics to present RESP-X Phase I data at ERS Congress

Alderley Park, Cheshire, U.K. Infex Therapeutics, a leading anti-infectives specialist, announces that Phase I data from RESP-X, the Company’s first-in-class anti-virulence antibody, will be presented in an oral presentation by Colm Leonard, Chief Clinical Officer at Infex, at...

Cessatech and Proveca announce world-wide excluding US commercial partnership for CT001

27 August 2024

Cessatech and Proveca announce world-wide excluding US commercial partnership for CT001

COPENHAGEN, Denmark, Aug. 26, 2024 /PRNewswire/ -- On 26 August – Cessatech A/S ("Cessatech" or "the Company") announces that the Company has entered into an exclusive commercialization agreement with Proveca Ltd - a global pharmaceutical company which specialises in the...